FY2025 · ended Dec 31, 2025 · Revenue $1.03M, +10429.4% YoY · Filed Mar 26, 2026
Dare Bioscience, Inc. (DARE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.0 million and a net loss of $13.4 million. Free cash flow was -$10.3 million. As of Jun 30, 2026 it held $12.6 million in cash and investments and $1.0 million in total debt.
Revenue (TTM)
$1.37M
+7816.7% vs year-ago TTM
Net income (TTM)
$-10.99M
+40.9% vs year-ago TTM
Operating cash flow (TTM)
$-11.29M
+1.8% vs year-ago TTM
Free cash flow (TTM)
$-11.76M
+0.3% vs year-ago TTM
EPS (TTM)
$-0.78
+63.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
14.56M
+64.5% vs prior year
Net cash
$11.60M
as of Jun 30, 2026
Operating margin
-813.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DARE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1401914
- Former names
- Cerulean Pharma Inc. (until Jul 5, 2017); Tempo Pharmaceuticals Inc (until Jan 22, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.0M | $9,784 | $2.8M | $10.0M | — |
| Operating income | -$13.6M | -$23.5M | -$30.9M | -$31.4M | -$39.1M |
| Net income | -$13.4M | -$4.1M | -$30.2M | -$30.9M | -$38.7M |
| Diluted EPS | -$1.20 | -$0.48 | -$4.15 | -$0.37 | -$0.63 |
| Operating cash flow | -$9.9M | $5.5M | -$38.9M | -$18.1M | -$28.8M |
| Free cash flow | -$10.3M | $4.9M | -$39.5M | -$18.2M | -$28.8M |
| Total assets | $32.5M | $22.1M | $21.3M | $43.8M | $55.8M |
| Total liabilities | $29.6M | $28.1M | $26.3M | $32.7M | $17.1M |
| Stockholders' equity | $2.8M | -$6.0M | -$5.0M | $11.1M | $38.8M |
| Cash and investments | $24.7M | $15.7M | $10.5M | $34.7M | $51.7M |
| Total debt | $2.7M | $1.3M | $1.4M | $489,000 | $270,500 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 2, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 11, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Aug 17, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
All 777 Dare Bioscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.